Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
Reiner Bonnet, MD
Adjunct Professor, Medicine
School of Medicine
Research & Grantsmanship    Funded Research Project (PI)
  • Phase 2, multicenter, randomized, double- blind, parallel- group, placebo- controlled study evaluating the safety and efficacy of treatment with Ustekinumab or Golimumab in subjects with chronic Sarcoidosis  1275148SCD2001  ( 7/2010 - 9/2011 )
  • Phase 2, multicenter, multinational, randomized, double- blind, placebo- controlled, parallel- group, dose- ranging Study evaluating the safety and efficacy of CNTO 888 administered intravenously in subjects with Ideopathic Pulmonary Fibrosis  CNTO888PUL2001  ( 9/2010 - 11/2010 )
  • Double blind, multicentre, parallel group, randomised, controlled Trial to evaluate the possible benefit of isoniazid dose adjustment to the genotype for NAT2 patients with Pulmonary Tuberculosis ( 4/2008 - 9/2010 )
    IDANAT2
  • Randomized, placebo- controlled, double- blind, multicenter Study to evaluate safety and efficacy of Ciprofloxacin inhale compared to placebo in patients with non cystic fibrosis Bronchiectasis  BAY q3939/12965  ( 9/2009 - 3/2010 )
  • Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in patients with  advanced upper lobe predominant Emphysema  (03-C08-003PLV)  ( 6/2009 - 3/2010 )
  • A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with Paclitaxel and Carboplatin as first-line treatment for locally advanced or metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC). ( 11/2008 - 7/2009 )
  • Nasal Transmucosal Fentanyl Citrate (NTFC) versus oral Morphine Sulphate (OMS): A double-blind, double dummy, randomised, multi-centre, comparative cross-over study for the treatment of breakthrough pain in cancer patients. ( 9/2007 - 4/2009 )
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis ( 3/2006 - 12/2008 )
  • A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage Ib or II Non-Small Cell Lung Cancer ( 12/2005 - 12/2008 )
  • Nicht-invasive Beatmung bei Patienten mit schwerer chronischer obstruktiver Bronchitis und Emphysem (COPD) ( 9/2005 - 12/2008 )
  • A phase III, international, randomised, double-blind, parallel-group, multi-centre study to assess the efficacy of ZD6474 (ZACTIMA) plus Best Supportive Care versus Placebo plus Best Supportive Care in patients with locally advanced or metastatic (Stage IIIB - IV) Non Small Cell Lung Cancer (NSCLC)after prior therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ( 11/2006 - 11/2008 )
  • Phase 2, randomized, double blind, Placebo-Controlled dose and schedule finding trial to evaluate the safety and efficacy of AMG 531 for treatment of chemotherapy-induced Thrombocytopenia in subjects with advanced Non-Small Cell Lung Cancer already receiving Gemcitabine and Platinum. ( 6/2007 - 7/2008 )
  • Offene, randomisierte, multizentrische Phase II Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Erlotinib vs. Carboplatin/Vinorelbin bei Patienten mit unvorbehandeltem NSCLC im fortgeschrittenen Stadium in höherem Lebensalter (> 70 Jahre). ( 4/2007 - 7/2008 )
  • A phase III, randomized, double-blinded, multi-center study to assess the efficacy of Docetaxel (Taxotere) in combination with ZD6474 (Zactima) versus Docetaxel (Taxotere) in combination with Placebo in patients with locally advanced or metastatic (Stage IIIb - IV) Non-small Cell Lung Cancer (NSCLC) after failure of 1st line Anti-Cancer therapy. ( 6/2007 - 2/2008 )
  • The INPACT study (Improving with Nadroparin the Prognosis in Advanced Cancer Treatment). A randomized, controlled trial to evaluate the effects of Nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas or prostate. ( 2/2007 - 1/2008 )
  • A Phase III, multicenter, randomized, double-blind, active controlled, parallel group study of the safety and efficacy of the intravenous and oral formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in combination with Ondansetron and Dexamethasone for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. ( 9/2006 - 5/2007 )
  • "Doppelblinde, randomisierte, multizentrische, Placebo-kontrollierte Dosisfindungsstudie mit parallelen Gruppen zur Beurteilung der Wirksamkeit, Sicherheit und Pharmakokinetik des Thrombopoetinrezeptoragonisten (SB-497115-GR), oral verabreicht in Dosen von 50, 75 und 100 mg an Krebspatienten, die mehrere Zyklen einer Chemotherapie erhalten." ( 10/2005 - 12/2006 )
  • A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD ( 4/2006 - 7/2006 )
  • Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cisplatin plus Best Supportive Care or Best Supportive Care alone in Stage III Non Small Cell Lung Cancer (NSCLC): A randomized Phase III study. ( 11/2006 - Present )
  • "Familienstudie zur Untersuchung des Einflußes von Genen für metabolisierende Enzyme und zellzyklus-relevanter Gene auf die Suszeptibilität für Lungenkrebs im jungen Alter." Es wird der Einfluß ausgewählter Polymorphismen in Kandidatengenen untereinander sowie deren Wechselwirkung mit Tabakrauch auf die Entstehung von Lungenkrebs untersucht. Multizentrisch werden Lungenkrebspatienten (Indexprobanden) mit einem Erkrankungsalter von höchstens 50 Jahren, falls möglich deren Eltern, Geschwister und Kinder über 18 Jahren einschließlich dem dazugehörigen zweiten Elternteil rekrutiert. ( 7/2006 - Present )
  • ( 9/2000 - Present )
  • (*)
  Abstracts Reporting Research -- Peer Reviewed
  • Mäder, I., R. Bonnet:. "Bronchoskopische Fibrinklebung als Mittel der Wahl bei iatrogenen Tracheaverletzungen. ." Pneumologie 59. (2005): S37-. ( 1/2005 )
  • Schmücking, M., A. Niesen, R. B. Bonnet, C. P. Schneider, N. Presselt, T. G. Wendt, R. P. Baum: . "Ist der F-18 FDG Uptake (SUV) wirklich ein unabhängiger Prognoseparameter für nicht-kleinzellige Lungenkarzinome? ." Nuklearmedizin 44. (2005): A 138 -. ( 1/2005 )
  • Schmuecking, M., C.P. Schneider, J. Soeldner, J. Leonhardi, N. Presselt, M Scheithauer, R.P. Baum, K.M. Mueller, T.G. Wendt, R. Bonnet: . "What is the role of F-18 FDG PET within randomized multicenter clinical trials for multi-modality treatment of non-small lung cancer stage III?." J Clin Oncol 23,S16. (2005): 665s-. ( 1/2005 )
  • Schmücking, M., J. Hagg, J. Leonhardi, R.P. Baum, T.G. Wendt, N. Presselt, C.P. Schneider, R. Bonnet, R. Messer, A.K. Buck, R. Wurm, K.D. Hamm, E. Röttinger, S.N. Röske, N.M. Blumstein: . "Ist eine molekulare Bestrahlungsplanung mittels PET klinisch relevant? Prospektive Analyse für verschiedene Tumorentitäten mit unterschiedlichen PET-Tracern. ." . Strahlenther Onkol 181,S1. (2005): 82-. ( 1/2005 )
  • Schmücking M., C.G. Blumstein, J. Leonhardi, R.P. Baum, N. Presselt, C.P. Schneider, T:G: Wendt, R. Bonnet, B. Krause, P. Messer, R. Wurm, K.D. Hamm, E. Röttinger, S.N. Reske, N.M. Blumstein: . "Verändertes Therapiemanagement durch PET ? Prospektive Analysen für verschiedene Tumorentitäten mit unterschiedlichen PET-Tracern. ." Strahlenther Onkol S1 181,S1. (2005): 83-. ( 1/2005 )
  • Schmuecking, M., R.P. Baum, S.M. Liesenfeld, M. Scheithauer, N. Presselt, C.P. Schneider, A. Niesen, J. Leonhardi, A. Proeschild, T.G. Wendt, R. Bonnet. "Is the F-18FDG uptake (SUV) an independent prognostic factor for non-small cell lung cancer (NSCLC)?." Journal of Nuclear Medicine 45, S. (2004): 373P-. ( 12/2004 )
  • Schmuecking, M., R.P. Baum, S. M. Liesenfeld, N. Presselt, C.P. Schneider, A. Niesen, J. Leonhardi, R. Bonnet. T.G. Wendt, A. Schmidt, K. M. Mueller. "Correlation of metabolic remission and histological regression with survival in locally advanced lung cancer.." Journal of Nuclear Medicine 45, S. (2004): 37P-. ( 12/2004 )
  • Schmuecking, M., R.P.Baum, S,M. Liesenfeld, M. Scheithauer, N. Presselt, C.P. Schneider, A. Niesen, J. Leonhardi, T.G. Wendt, J. Dunst, K.H. Kloetzer, U. Schalldach, J. Scheibe, R. Bonnet: . "Molecular radiation treatment planning with F-18 FDG-PET in non-small cell lung cancer (NSCLC)." Journal of Nuclear Medicine 45 S. (2004): 37P-. ( 12/2004 )
  • Maeder, I., R. Bonnet: . "Argonplasmacoagulation (APC) is the treatment of choice in the therapy of severe tracheopathia osteochondroplastica (TPO). ." Proceedings XIII th World Congress for Bronchology, Barcelona . (2004): P018-. ( 12/2004 )
  • Maeder, I., R. Bonnet: . "Bronchoscopic fibrin sealing is the treatment of choice in iatrogenic tracheal injuries. ." Proceedings XIII th World Congress for Bronchology, Barcelona . (2004): P053-. ( 12/2004 )
  • Weber, M., R. Bonnet, A, Schmidt, J. Sänger. "Adjuvante medikamentöse Therapie einer pulmonalen Mycobacterium-abscessus-Infektion mit Interferon-Gamma bei einem immunkompetenten Patienten. ." Atemw.-Lungenkrkh 30 . (2004): 529 -. ( 12/2004 )
  • Mäder, I., R. Bonnet. "Bronchoskopische Fibrinklebung als Mittel der Wahl bei iatrogenen Tracheaverletzungen. ." Atemw.-Lungenkrkh. 30. (2004): 528-. ( 12/2004 )
  • Mäder, I., R. Bonnet. "Argonplasmakoagulation in der Therapie der schweren Tracheabronchopathia osteochondroplastica. ." Atemw.-Lungenkrkh. 30. (2004): 527-. ( 12/2004 )
  • Bonnet, R., R. Rosell, J. Strausz, E. Sanches, M. Provencio, J.-M. Vernejoux, H. Lena, M. L. Gershanovich, B. Boussard, J. von Pawel. ": Irinitecan (Iri) plus docetaxel (Doc) every 3 weeks in chemotherapy naïve patients (pts) with inoperable non-small cell lung cancer (NSCLC): results of a phase II study. ." Annals of Oncology 15,S3. (2004): iii177 -. ( 12/2004 )
  • Schneider, C.-P., R. Bonnet. "First-line treatment with docetaxel and platinum in patients with advanced non-small cell lung cancer (NSCLC): Clinical experience from a single institution. ." Annals of Oncology 15,S3. (2004): iii178-. ( 12/2004 )
  Abstracts Reporting Research -- Non-Peer Reviewed
  • Study to assess the unilaterale bronchoscopic thermal Vaporablation (BTVA) in patients with heterogenous emphysema of the upper lobe  CSP-00808  ( 12/2009 - Present )